Tianyin granted Chinese approval for simvastatin tablets

Tianyin’s simvastatin tablets are sold by prescription in hospitals, which is said to be the major sales channel for drugs in China. Tianyin will start producing simvastatin tablets in early August 2008, while selling it through strategic distributor partners throughout China.

Simvastatin is a statin drug which is used to control hypercholesterolemia and treat coronary heart diseases. This is said to be the only statin type drug approved by the Chinese State Food and Drug Administration (SFDA) to treat these conditions and is highly effective, with fewer side effects when compared to other similar drugs.

According to the company, simvastatin can reduce the mortality rate of coronary heart diseases, coronary artery diseases, and cerebral stroke by 17%, 24% and 25%, respectively.

Guoqing Jiang, chairman and CEO of Tianyin, said: “We are optimistic that the additional drugs that are currently in our development pipeline for SFDA approval will be able to move through this process toward commercialization.”